Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) PT at $14.00

Sana Biotechnology, Inc. (NASDAQ:SANA) has earned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $12.25.

Several research analysts have recently issued reports on SANA shares. HC Wainwright upped their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday. They issued a “buy” rating and a $7.00 target price for the company. Finally, TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th.

Insider Activity at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This trade represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is owned by insiders.

Institutional Trading of Sana Biotechnology

Several hedge funds have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after acquiring an additional 4,438,949 shares during the period. State Street Corp lifted its stake in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after acquiring an additional 269,274 shares during the period. Geode Capital Management LLC lifted its stake in shares of Sana Biotechnology by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock valued at $5,206,000 after purchasing an additional 26,601 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Sana Biotechnology by 7.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,108,617 shares of the company’s stock valued at $5,068,000 after purchasing an additional 219,498 shares during the period. Finally, Integral Health Asset Management LLC lifted its stake in shares of Sana Biotechnology by 11.1% in the fourth quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $3,260,000 after purchasing an additional 200,000 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Trading Up 10.6 %

Shares of Sana Biotechnology stock opened at $2.93 on Friday. The company has a fifty day simple moving average of $3.03 and a 200-day simple moving average of $3.25. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50. The stock has a market cap of $654.18 million, a price-to-earnings ratio of -2.09 and a beta of 1.63.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.